Diego Moya‐Nájera, Ángel Moya‐Herraiz, Luis Compte‐Torrero, David Hervás, Sebastien Borreani, Joaquin Calatayud, Marina Berenguer, Juan C. Colado – 27 July 2017 – Although currently moderate and high intensity concurrent physical exercise is prescribed in populations with special needs due to its greater effect on physical condition and health‐related quality of life (HRQOL), there are no data in the liver transplantation (LT) setting.

Sandeep Singh Sidhu, Barjesh Chander Sharma, Omesh Goyal, Harsh Kishore, Navpreet Kaur – 27 July 2017 – High‐quality data on the efficacy of L‐ornithine L‐aspartate (LOLA) in patients with cirrhosis and bouts of overt hepatic encephalopathy (OHE) are missing. We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in patients with cirrhosis. In this prospective, double‐blind, randomized, placebo‐controlled trial conducted at two tertiary care institutes in India, 370 patients with cirrhosis and bouts of OHE were screened.

Jiwei Zhang, Zhe Li, Longzi Liu, Qifeng Wang, Shengli Li, Di Chen, Zhixiang Hu, Tao Yu, Jie Ding, Jinjun Li, Ming Yao, Shenglin Huang, Yingjun Zhao, Xianghuo He – 26 July 2017 – Long noncoding RNAs can serve as oncogenes or tumor suppressors in human cancer; however, their biological functions and underlying mechanism in hepatocarcinogenesis are largely unknown. Here, we report a novel tumor suppressor long noncoding RNA on chromosome 8p12 (termed TSLNC8) that is frequently deleted and down‐regulated in hepatocellular carcinoma (HCC) tissues.

Jin‐Kyu Park, Yasuko Iwakiri – 26 July 2017

Koichi Fujisawa, Taro Takami, Toshihiko Matsumoto, Naoki Yamamoto, Isao Sakaida – 26 July 2017 – Liver cirrhosis can disturb circadian rhythms, decreasing patient quality of life. Changes in metabolic products in cirrhosis are poorly understood. We evaluated changes in liver metabolism products using a thioacetamide‐induced mouse model of liver cirrhosis exhibiting circadian rhythm disturbance.

Shikun Yang, Jianhua Rao – 26 July 2017

Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Naoya Kanogawa, Tenyu Motoyama, Eiichiro Suzuki, Akinobu Tawada, Kazue Nagai, Tomoo Nakagawa, Takeshi Sugawara, Hideki Hanaoka, Fumihiko Kanai, Osamu Yokosuka – 26 July 2017 – This randomized, double‐blind, placebo‐controlled trial evaluated dexamethasone efficacy at preventing fever, anorexia, and nausea/vomiting, the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

Loreta A.

Romina Fiorotto, Mariangela Amenduni, Valeria Mariotti, Luca Fabris, Carlo Spirli, Mario Strazzabosco – 24 July 2017 – Cystic fibrosis transmembrane conductance regulator (CFTR), the channel mutated in cystic fibrosis (CF), is expressed by the biliary epithelium (i.e., cholangiocytes) of the liver. Progressive clinical liver disease (CF‐associated liver disease; CFLD) occurs in around 10% of CF patients and represents the third leading cause of death.

Romina Fiorotto, Mariangela Amenduni, Valeria Mariotti, Luca Fabris, Carlo Spirli, Mario Strazzabosco – 24 July 2017 – Cystic fibrosis transmembrane conductance regulator (CFTR), the channel mutated in cystic fibrosis (CF), is expressed by the biliary epithelium (i.e., cholangiocytes) of the liver. Progressive clinical liver disease (CF‐associated liver disease; CFLD) occurs in around 10% of CF patients and represents the third leading cause of death.